Sanjay Khandelwal

Sanjay Khandelwal

Auto-generated profile, based on publicly available information

Sanjay Khandelwal

Division of Hematology, Duke University Medical Center , Durham, NC

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

15 September 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
RSRobin Schmitz
Robin Schmitz
ZFZachary W. Fitch
Zachary W. Fitch
PSPaul M. Schroder
Paul M. Schroder
ACAshley Y. Choi
Ashley Y. Choi
MMMiriam Manook
Miriam Manook
SKStuart Knechtle
Stuart Knechtle
Sensitized kidney transplant recipients experience high rates of antibody-mediated rejection due to the presence of donor-specific antibodies and immunologic memory. Here we show that transient peri-transplant treatment with the central complement component C3 inhibitor Cp40 significantly prolongs median allograft survival in a sensitized nonhuman primate model. Despite donor-specific antibody levels remaining high, fifty percent of Cp40-treated primates maintain normal kidney function beyond the last day of treatment. Interestingly, presence of antibodies of the IgM class associates with reduced median graft survival (8 vs. 40 days;p = 0.02). Cp40 does not alter lymphocyte depletion by rhesus-specific anti-thymocyte globulin, but inhibits lymphocyte activation and proliferation, resulting in reduced antibody-mediated injury and complement deposition. In summary, Cp40 prevents acute antibody-mediated rejection and prolongs graft survival in primates, and inhibits T and B cell activation and proliferation, suggesting an immunomodulatory effect beyond its direct impact on antibody-mediated injury.

25 January 2024 in Blood
Verified
Journal Article
Closed access
PDF file
PLPengfei Liang
Pengfei Liang
YZYang Zhang
Yang Zhang
YWYui Chun S. Wan
Yui Chun S. Wan
SMShang Ma
Shang Ma
PDPing Dong
Ping Dong
HYHuanghe Yang
Huanghe Yang
Cell-surface exposure of phosphatidylserine (PS) is essential for phagocytic clearance and blood clotting. Although a calcium-activated phospholipid scramblase (CaPLSase) has long been proposed to mediate PS exposure in red blood cells (RBCs), its identity, activation mechanism, and role in RBC biology and disease remain elusive. Here, we demonstrate that TMEM16F, the long-sought-after RBC CaPLSase, is activated by calcium influx through the mechanosensitive channel PIEZO1 in RBCs. PIEZO1-TMEM16F functional coupling is enhanced in RBCs from individuals with hereditary xerocytosis (HX), an RBC disorder caused by PIEZO1 gain-of-function channelopathy. Enhanced PIEZO1-TMEM16F coupling leads to an increased propensity to expose PS, which may serve as a key risk factor for HX clinical manifestations including anemia, splenomegaly, and postsplenectomy thrombosis. Spider toxin GsMTx-4 and antigout medication benzbromarone inhibit PIEZO1, preventing force-induced echinocytosis, hemolysis, and PS exposure in HX RBCs. Our study thus reveals an activation mechanism of TMEM16F CaPLSase and its pathophysiological function in HX, providing insights into potential treatment.

6 December 2018 in Blood
Verified
Journal Article
Closed access
PDF file
SKSanjay Khandelwal
Sanjay Khandelwal
JRJoann Ravi
Joann Ravi
LRLubica Rauova
Lubica Rauova
AJAlexandra Johnson
Alexandra Johnson
GLGrace M. Lee
Grace M. Lee
GAGowthami M. Arepally
Gowthami M. Arepally
The mechanisms by which exposure to heparin initiates antibody responses in many, if not most, recipients are poorly understood. We recently demonstrated that antigenic platelet factor 4 (PF4)/heparin complexes activate complement in plasma and bind to B cells. Here, we describe how this process is initiated. We observed wide stable variation in complement activation when PF4/heparin was added to plasma of healthy donors, indicating a responder “phenotype” (high, intermediate, or low). Proteomic analysis of plasma from these healthy donors showed a strong correlation between complement activation and plasma immunoglobulin M (IgM) levels (r = 0.898; P < .005), but not other Ig isotypes. Complement activation response to PF4/heparin in plasma displaying the low donor phenotype was enhanced by adding pooled IgM from healthy donors, but not monoclonal IgM. Depletion of IgM from plasma abrogated C3c generation by PF4/heparin. The complement-activating features of IgM are likely mediated by nonimmune, or natural, IgM, as cord blood and a monoclonal polyreactive IgM generate C3c in the presence of PF4/heparin. IgM facilitates complement and antigen deposition on B cells in vitro and in patients receiving heparin. Anti-C1q antibody prevents IgM-mediated complement activation by PF4/heparin complexes, indicating classical pathway involvement. These studies demonstrate that variability in plasma IgM levels correlates with functional complement responses to PF4/heparin. Polyreactive IgM binds PF4/heparin, triggers activation of the classical complement pathway, and promotes antigen and complement deposition on B cells. These studies provide new insights into the evolution of the heparin-induced thrombocytopenia immune response and may provide a biomarker of risk.

6 October 2016 in Blood
Verified
Journal Article
Closed access
SKSanjay Khandelwal
Sanjay Khandelwal
GLGrace M. Lee
Grace M. Lee
CHC. Garren Hester
C. Garren Hester
MPMortimer Poncz
Mortimer Poncz
SMSteven McKenzie
Steven McKenzie
GAGowthami M. Arepally
Gowthami M. Arepally
Key Points: PF4/heparin ultra-large complexes activate complement and bind preferentially to B cells via CR2 (CD21). Complement-fixed PF4/heparin complexes can be detected on circulating B cells in patients receiving heparin therapy.

25 November 2021 in Blood
Verified
Journal Article
Open access
PDF file
SKSanjay Khandelwal
Sanjay Khandelwal
ABAyiesha Barnes
Ayiesha Barnes
LRLubica Rauova
Lubica Rauova
ASAmrita Sarkar
Amrita Sarkar
ARAnn H. Rux
Ann H. Rux
DCDouglas B. Cines
Douglas B. Cines
Heparin-induced thrombocytopenia (HIT) is a prothrombotic disorder mediated by ultra-large immune complexes (ULICs) containing immunoglobulin G (IgG) antibodies to a multivalent antigen composed of platelet factor 4 and heparin. The limitations of current antithrombotic therapy in HIT supports the need to identify additional pathways that may be targets for therapy. Activation of FcγRIIA by HIT ULICs initiates diverse procoagulant cellular effector functions. HIT ULICs are also known to activate complement, but the contribution of this pathway to the pathogenesis of HIT has not been studied in detail. We observed that HIT ULICs physically interact with C1q in buffer and plasma, activate complement via the classical pathway, promote codeposition of IgG and C3 complement fragments (C3c) on neutrophil and monocyte cell surfaces. Complement activation by ULICs, in turn, facilitates FcγR-independent monocyte tissue factor expression, enhances IgG binding to the cell surface FcγRs, and promotes platelet adhesion to injured endothelium. Inhibition of the proximal, but not terminal, steps in the complement pathway abrogates monocyte tissue factor expression by HIT ULICs. Together, these studies suggest a major role for complement activation in regulating Fc-dependent effector functions of HIT ULICs, identify potential non-anticoagulant targets for therapy, and provide insights into the broader roles of complement in immune complex–mediated thrombotic disorders.